Johns Hopkins Launches Immunotherapy Center
News Mar 30, 2016
A new institute studying immunology with the potential to eventually end all forms of cancer was announced today at Johns Hopkins by Vice President Joe Biden, Michael R. Bloomberg and more than a dozen additional supporters of this initiative. Embracing the vice president’s “moonshot” initiative to cure cancer, the new Bloomberg~Kimmel Institute for Cancer Immunotherapy was founded with gifts from Michael R. Bloomberg, philanthropist, entrepreneur and three-term mayor of New York City, and Jones Apparel Group founder Sidney Kimmel, who each contributed $50 million. An additional $25 million for the center is thanks to more than a dozen additional supporters.
Immunotherapy is a central element of the Obama administration’s new moonshot to cure cancer. It has the potential to cure and end all forms of cancer, which makes it one of the most promising avenues of cancer research today. Currently the most rapidly advancing approach to cancer treatment, immunotherapy seeks to redirect patients’ highly individual immune systems to target, detect and destroy cancer cells.
The institute will further strengthen Johns Hopkins’ world-class program in cancer immunology, uniting the Johns Hopkins Kimmel Cancer Center experts with the immunology, genetics, microbiology and biomedical engineering experts throughout Johns Hopkins in a concentrated effort involving over 100 scientists and clinicians.
“We are at the forefront of an emerging and promising field of cancer research and treatment,” said Paul Rothman, M.D., dean and CEO of Johns Hopkins Medicine. “We are grateful for these tremendous gifts which will help us accelerate the already rapid pace of discoveries in immunotherapy.”
How Funds Will Be Used
While funds for the new institute will primarily support research, they also will be used to recruit additional scientists; provide additional infrastructure for engineering cellular products related to immunotherapy research; enhance partnerships with the private sector, including biotech and pharma; and invest in critical technology development, such as new ways to profile the immune response inside the tumor. Research at the institute will focus particularly on melanoma, colon, pancreatic, urologic, lung, breast and ovarian cancers.
According to Drew Pardoll, M.D., Ph.D., the institute’s inaugural director, “We believe the focused and collaborative research made possible through the Bloomberg~Kimmel Institute for Cancer Immunotherapy will advance immunotherapies to the point where the immune system will ultimately be able to beat 100 percent of cancers. The potential to control or cure even the most advanced, treatment-resistant cancers has been elusive until now.”
Bloomberg and Kimmel: A History of Support for Health Funding
Sidney Kimmel and Michael Bloomberg each have a long history of support for Johns Hopkins.
Bloomberg, a 1964 alumnus of The Johns Hopkins University and chairman of its board of trustees from 1996 to 2002, has given more than $1.2 billion to the university and the Johns Hopkins Health System since graduating. Funding from Bloomberg has contributed to a physics building, a school of public health, a children’s hospital, a stem cell research institute, a malaria institute and a library wing. He has also financed 20 percent of all need-based financial aid grants to undergraduates, with over 2,000 scholarships committed over the next several years. Announced in January 2013, Bloomberg committed an additional $250 million to recruit 50 faculty members as Bloomberg Distinguished Professors. The majority of this gift is dedicated to creating 50 new interdisciplinary professorships, galvanizing people, resources, research and educational opportunities to address major world problems.
“Ending all cancer would rank among humanity’s greatest achievements, and immunotherapy is bringing that dream within reach. This new institute will build on the pioneering work that doctors and researchers at Johns Hopkins have done in immunotherapy and help fuel new advances and discoveries. It’s an honor to join Vice President Biden in the moonshot effort he’s leading to end cancer and also to partner with Sidney Kimmel, whose generous and committed support for cancer research is saving lives,” says Bloomberg.
Since 2001, Kimmel has contributed $157 million; in recognition of that generosity, Johns Hopkins named its cancer center after him. Kimmel also has given an additional $2.4 million to support 12 young cancer scientists at Johns Hopkins as part of his national Kimmel Scholars Program.
“I could not be more honored to partner with Mike Bloomberg and capture the opportunity to advance immunotherapy research at this critical moment,” Kimmel says. “Having been committed to cancer research for more than 20 years, it simply thrills me to know that the scientists at the Johns Hopkins Kimmel Cancer Center see a new light at the end of the tunnel.”
“Michael Bloomberg and Sidney Kimmel are visionaries,” says Ronald J. Daniels, president of Johns Hopkins University. “Their philanthropy has already fostered remarkable innovation throughout Johns Hopkins, transforming the landscape of public health and cancer research. The new Bloomberg-Kimmel Institute builds on that legacy, giving us the latitude to dream big as we accelerate our efforts to end all forms of cancer.”
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, based in Baltimore, Maryland, is one of 45 centers designated by the National Cancer Institute as a comprehensive center.
Almost 95% of people with early-diagnosed breast cancer will require surgery and it’s often the first line of treatment for people with brain tumors, for example. But despite improvements in surgical techniques over the past decade, the cancer often comes back after the procedure. Now, a team has developed a spray gel embedded with immune-boosting drugs that could help.READ MORE
23rd World Congress on Pediatrics, Neonatology & Primary Care
Nov 22 - Nov 23, 2019